Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily
with chronic dosing in metformin-treated subjects with type 2 diabetes